<tei>
    <teiHeader>
        <fileDesc xml:id="_Abdulrahman 2012.pdf"/>
    </teiHeader>
    <text xml:lang="en">


		<figure type="table">

            <head>Table </head>
 
            <label>1 </label>
 
            <head>Survey population and study sampling frame<lb/> </head>
<lb/> 
            <table>Population<lb/> Individuals Ն4 yr old diagnosed with AR, symptomatic, or being<lb/> treated for allergic rhinitis in the past 12 mo<lb/> Sampling frame<lb/> Telephone and in-person screening of national or major city<lb/> sample<lb/> Interview length<lb/> Range, 20-75 min; mean, 36.2 min<lb/> Region<lb/> No. of Households<lb/> Screened<lb/> Completed<lb/> Sample<lb/> Egypt*<lb/> 1274<lb/> 100<lb/> Iran* §<lb/> 2313<lb/> 100<lb/> Lebanon*<lb/> 790<lb/> 100<lb/> Saudi Arabia#<lb/> 1639<lb/> 100<lb/> United Arab Emirates#<lb/> 1395<lb/> 101<lb/> Total<lb/> 7411<lb/> 501<lb/> *Participants screened via in-person interview.<lb/> #Participants screened via telephone.<lb/> §Iran is a nonprobability sample and interviews were not conducted in a<lb/> similar fashion to other countries.<lb/> AR ϭ allergic rhinitis.<lb/> S4<lb/> November-December 2012, Vol. 26, No. 6<lb/> D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>2 </label>
 
            <head>Survey participants demographics<lb/> Parameter<lb/> </head>
<lb/> 
            <table>Sex (unweighted)<lb/> Male<lb/> 44.7%<lb/> Female<lb/> 55.3%<lb/> Age (unweighted)<lb/> Children (4-17 yr)<lb/> Mean, 10.7 yr; n ϭ92<lb/> Adults (18-88 yr)<lb/> Mean, 35.0 yr; n ϭ409<lb/> Education level of all respondents and caregivers of children<lb/> (unweighted)<lb/> No school<lb/> 3.4%<lb/> Primary education<lb/> 8.2%<lb/> Secondary education university<lb/> 87%<lb/> Do not know<lb/> 0.4%<lb/> Refused to answer<lb/> 1.2%<lb/> Health insurance types (weighted)<lb/> Private<lb/> 36%<lb/> Public<lb/> 34%<lb/> Both<lb/> 5%<lb/> None<lb/> 22%<lb/> Do not know/refused<lb/> 2%<lb/> First diagnosed with AR (weighted)<lb/> Age<lb/> Mean, 20.5 yr<lb/> Smoking status (weighted)<lb/> Yes<lb/> 40%<lb/> No<lb/> 59%<lb/> Refused to answer<lb/> 1%<lb/> Pets in household (weighted)<lb/> Yes<lb/> 24%<lb/> No<lb/> 74%<lb/> Refused to answer<lb/> 2%<lb/> Diagnosed with asthma (weighted)<lb/> Yes<lb/> 14%<lb/> No<lb/> 86%<lb/> Do not know/refused to answer<lb/> 0%<lb/> Asthma exacerbation within the past year (weighted)<lb/> Yes<lb/> 68%<lb/> No<lb/> 26%<lb/> Do not know/refused to answer<lb/> 6%<lb/> American Journal of Rhinology &amp; Allergy<lb/> S5<lb/> D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>3 </label>
 
            <head>Prevalence and patterns of diagnosed AR in the Middle East<lb/> </head>
<lb/> 
            <table>Parameter<lb/> Middle East<lb/> Egypt<lb/> Iran<lb/> Lebanon<lb/> Saudi Arabia<lb/> United Arab Emirates<lb/> Respondents with physician diagnosis of (%)<lb/> Nasal allergies<lb/> 57<lb/> 75<lb/> 39<lb/> 63<lb/> 52<lb/> 66<lb/> Sinusitis<lb/> 26<lb/> 17<lb/> 27<lb/> 34<lb/> 43<lb/> 36<lb/> AR<lb/> 16<lb/> 8<lb/> 30<lb/> 14<lb/> 3<lb/> 4<lb/> Sinus disease<lb/> 5<lb/> 5<lb/> 4<lb/> 18<lb/> 2<lb/> 5<lb/> Asthma<lb/> 14<lb/> 13<lb/> 3<lb/> 41<lb/> 33<lb/> 36<lb/> Medical specialty of physician making first diagnosis (most frequently seen for AR) (%)<lb/> Otolaryngologist<lb/> 54 (59)<lb/> 60 (65)<lb/> 44 (53)<lb/> 33 (34)<lb/> 63 (61)<lb/> 58 (50)<lb/> Allergist<lb/> 12 (19)<lb/> 23 (21)<lb/> 4 (23)<lb/> 14 (29)<lb/> 6 (7)<lb/> 4 (5)<lb/> Internal medicine<lb/> 15 (8)<lb/> 2 (0)<lb/> 36 (17)<lb/> 2 (1)<lb/> 0 (6)<lb/> 0 (3)<lb/> General practitioner/family practice<lb/> 12 (8)<lb/> 10 (9)<lb/> 13 (4)<lb/> 22 (13)<lb/> 13 (13)<lb/> 13 (19)<lb/> Respiratory specialist<lb/> 3 (3)<lb/> 4 (5)<lb/> 2 (3)<lb/> 10 (10)<lb/> 0 (0)<lb/> 0 (0)<lb/> Pediatrician<lb/> 2 (2)<lb/> 1 (0)<lb/> 0 (0)<lb/> 19 (13)<lb/> 4 (11)<lb/> 8 (15)<lb/> Respondents reporting allergy testing being done (%)<lb/> Skin test only<lb/> 10<lb/> 18<lb/> 1<lb/> 5<lb/> 13<lb/> 7<lb/> Blood test only<lb/> 13<lb/> 5<lb/> 20<lb/> 11<lb/> 13<lb/> 21<lb/> Both<lb/> 31<lb/> 13<lb/> 60<lb/> 35<lb/> 9<lb/> 16<lb/> Neither<lb/> 46<lb/> 64<lb/> 19<lb/> 49<lb/> 65<lb/> 56<lb/> Respondent perceived frequency of AR (%)<lb/> Intermittent<lb/> 65<lb/> 68<lb/> 57<lb/> 55<lb/> 79<lb/> 57<lb/> Persistent<lb/> 30<lb/> 19<lb/> 43<lb/> 44<lb/> 21<lb/> 42<lb/> Not sure<lb/> 5<lb/> 13<lb/> 0<lb/> 1<lb/> 0<lb/> 1<lb/> Respondent reported triggers for AR (%)<lb/> Dust<lb/> 71<lb/> 63<lb/> 79<lb/> 79<lb/> 74<lb/> 59<lb/> Pollution<lb/> 47<lb/> 49<lb/> 61<lb/> 36<lb/> 8<lb/> 21<lb/> Perfume<lb/> 46<lb/> 24<lb/> 75<lb/> 46<lb/> 36<lb/> 20<lb/> Tobacco smoke<lb/> 46<lb/> 27<lb/> 83<lb/> 40<lb/> 9<lb/> 11<lb/> Hot or spicy food<lb/> 40<lb/> 28<lb/> 72<lb/> 10<lb/> 4<lb/> 7<lb/> Weather<lb/> 38<lb/> 44<lb/> 32<lb/> 65<lb/> 31<lb/> 37<lb/> Chemicals<lb/> 38<lb/> 28<lb/> 56<lb/> 42<lb/> 22<lb/> 20<lb/> Air conditioning<lb/> 34<lb/> 52<lb/> 21<lb/> 17<lb/> 15<lb/> 51<lb/> Viruses or colds<lb/> 26<lb/> 25<lb/> 35<lb/> 42<lb/> 4<lb/> 7<lb/> Exercise<lb/> 20<lb/> 14<lb/> 37<lb/> 12<lb/> 0<lb/> 2<lb/> Grass<lb/> 19<lb/> 3<lb/> 43<lb/> 23<lb/> 3<lb/> 1<lb/> Stress<lb/> 14<lb/> 29<lb/> 5<lb/> 6<lb/> 0<lb/> 5<lb/> Animals<lb/> 13<lb/> 11<lb/> 18<lb/> 15<lb/> 7<lb/> 4<lb/> Emotions<lb/> 11<lb/> 18<lb/> 10<lb/> 6<lb/> 0<lb/> 1<lb/> Alcohol<lb/> 10<lb/> 3<lb/> 23<lb/> 2<lb/> 0<lb/> 0<lb/> AR ϭ allergic rhinitis.<lb/> </table>
<lb/> 
            <note>S6<lb/> November-December 2012, Vol. 26, No. 6<lb/> </note>
<lb/> 
            <table>D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>4 </label>
 
            <head>Symptoms associated with AR in Middle East patients<lb/> </head>
<lb/> 
            <table>Parameter<lb/> Middle East<lb/> Egypt<lb/> Iran<lb/> Lebanon<lb/> Saudi Arabia<lb/> United Arab Emirates<lb/> Respondents reporting they still suffer from AR (%)<lb/> Still suffering from NA (%)<lb/> 98<lb/> 96<lb/> 100<lb/> 100<lb/> 96<lb/> 95<lb/> Respondents reporting use of medications for AR within past 12 mo (%)<lb/> Any medication<lb/> 92<lb/> 93<lb/> 100<lb/> 96<lb/> 69<lb/> 77<lb/> Oral allergy medications<lb/> 53<lb/> 59<lb/> 56<lb/> 49<lb/> 22<lb/> 27<lb/> Desensitization or immunotherapies<lb/> 42<lb/> 51<lb/> 41<lb/> 57<lb/> 19<lb/> 25<lb/> Nasal steroids<lb/> 84<lb/> 83<lb/> 98<lb/> 67<lb/> 59<lb/> 51<lb/> Respondents with symptom occurring every day or most days during worst allergy month in past year (%)<lb/> Runny nose<lb/> 57<lb/> 62<lb/> 69<lb/> 36<lb/> 20<lb/> 24<lb/> Nasal itching<lb/> 56<lb/> 57<lb/> 67<lb/> 32<lb/> 31<lb/> 30<lb/> Nasal congestion or stuffed up nose<lb/> 55<lb/> 46<lb/> 76<lb/> 69<lb/> 29<lb/> 40<lb/> Throat itching<lb/> 52<lb/> 56<lb/> 64<lb/> 22<lb/> 23<lb/> 18<lb/> Reduced sense of smell<lb/> 51<lb/> 67<lb/> 53<lb/> 32<lb/> 12<lb/> 16<lb/> Postnasal drip<lb/> 50<lb/> 60<lb/> 54<lb/> 45<lb/> 17<lb/> 20<lb/> Headache<lb/> 44<lb/> 64<lb/> 34<lb/> 38<lb/> 22<lb/> 13<lb/> Repeated sneezing<lb/> 44<lb/> 24<lb/> 70<lb/> 52<lb/> 31<lb/> 38<lb/> Watery or teary eyes<lb/> 41<lb/> 40<lb/> 55<lb/> 26<lb/> 13<lb/> 27<lb/> Cough<lb/> 40<lb/> 64<lb/> 26<lb/> 33<lb/> 15<lb/> 20<lb/> Red or itching eyes<lb/> 39<lb/> 32<lb/> 59<lb/> 14<lb/> 11<lb/> 21<lb/> Respondents experiencing moderately to extremely bothersome symptoms during AR attacks (%)<lb/> Runny nose<lb/> 83<lb/> 74<lb/> 93<lb/> 92<lb/> 76<lb/> 74<lb/> Nasal itching<lb/> 79<lb/> 72<lb/> 92<lb/> 84<lb/> 76<lb/> 81<lb/> Throat itching<lb/> 78<lb/> 75<lb/> 91<lb/> 82<lb/> 71<lb/> 84<lb/> Postnasal drip<lb/> 76<lb/> 77<lb/> 76<lb/> 90<lb/> 84<lb/> 84<lb/> Nasal congestion or stuffed up nose<lb/> 74<lb/> 62<lb/> 85<lb/> 93<lb/> 78<lb/> 83<lb/> Reduced sense of smell<lb/> 73<lb/> 76<lb/> 85<lb/> 78<lb/> 71<lb/> 74<lb/> Repeated sneezing<lb/> 66<lb/> 46<lb/> 86<lb/> 82<lb/> 79<lb/> 69<lb/> Headache<lb/> 64<lb/> 76<lb/> 83<lb/> 90<lb/> 66<lb/> 82<lb/> Cough<lb/> 63<lb/> 79<lb/> 78<lb/> 90<lb/> 74<lb/> 75<lb/> Red or itching eyes<lb/> 62<lb/> 49<lb/> 89<lb/> 80<lb/> 64<lb/> 75<lb/> Watery or teary eyes<lb/> 61<lb/> 47<lb/> 88<lb/> 81<lb/> 56<lb/> 83<lb/> Most bothersome symptom during AR attacks (respondent %)<lb/> Repeated sneezing<lb/> 28<lb/> 12<lb/> 45<lb/> 16<lb/> 19<lb/> 19<lb/> Headache<lb/> 15<lb/> 8<lb/> 22<lb/> 12<lb/> 14<lb/> 10<lb/> Cough<lb/> 9<lb/> 18<lb/> 2<lb/> 12<lb/> 9<lb/> 10<lb/> Nasal congestion<lb/> 9<lb/> 5<lb/> 7<lb/> 28<lb/> 17<lb/> 22<lb/> Runny nose<lb/> 8<lb/> 8<lb/> 10<lb/> 5<lb/> 5<lb/> 8<lb/> Level of symptom discomfort during allergy attack (respondent %)<lb/> Can not tolerate without relief<lb/> 49<lb/> 57<lb/> 43<lb/> 69<lb/> 38<lb/> 46<lb/> AR ϭ allergic rhinitis.<lb/> American Journal of Rhinology &amp; Allergy<lb/> S7<lb/> D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>5 </label>
 
            <head>Impact of AR on QOL in Middle East patients<lb/> </head>
<lb/> 
            <table>Parameter<lb/> Middle East<lb/> Egypt<lb/> Iran<lb/> Lebanon<lb/> Saudi Arabia<lb/> United Arab Emirates<lb/> Impact of AR on daily life (respondent %)<lb/> A moderate amount<lb/> 40<lb/> 57<lb/> 31<lb/> 24<lb/> 22<lb/> 26<lb/> A lot<lb/> 18<lb/> 16<lb/> 20<lb/> 14<lb/> 17<lb/> 20<lb/> Patients feelings during allergy season (symptoms experienced frequently) (respondent %)<lb/> Depressed<lb/> 26<lb/> 26<lb/> 23<lb/> 38<lb/> 29<lb/> 30<lb/> Tired<lb/> 40<lb/> 51<lb/> 27<lb/> 54<lb/> 39<lb/> 39<lb/> Miserable<lb/> 11<lb/> 15<lb/> 6<lb/> 32<lb/> 12<lb/> 11<lb/> Activity limitation (at least some) (respondent %)<lb/> Doing well at work/school<lb/> 72<lb/> 83<lb/> 69<lb/> 51<lb/> 55<lb/> 50<lb/> Outdoor activities<lb/> 65<lb/> 80<lb/> 59<lb/> 35<lb/> 48<lb/> 40<lb/> Indoor activities<lb/> 59<lb/> 78<lb/> 49<lb/> 16<lb/> 44<lb/> 38<lb/> Allergy interference with work/school (respondent %)<lb/> Missed work/school only<lb/> 13<lb/> 11<lb/> 14<lb/> 10<lb/> 15<lb/> 13<lb/> Interfered with work/school only<lb/> 8<lb/> 6<lb/> 5<lb/> 17<lb/> 17<lb/> 18<lb/> Missed and interfered<lb/> 35<lb/> 50<lb/> 30<lb/> 27<lb/> 13<lb/> 18<lb/> Work productivity (respondent %)<lb/> No allergy symptoms<lb/> 83<lb/> 79<lb/> 83<lb/> 87<lb/> 89<lb/> 84<lb/> Allergy symptoms at worst<lb/> 56<lb/> 61<lb/> 54<lb/> 52<lb/> 49<lb/> 59<lb/> AR sleep interference (getting to sleep) (respondent %)<lb/> Quite a bit troubled<lb/> 14<lb/> 9<lb/> 19<lb/> 16<lb/> 14<lb/> 13<lb/> Extremely troubled<lb/> 15<lb/> 14<lb/> 12<lb/> 19<lb/> 23<lb/> 28<lb/> AR sleep interference (waking up during night) (respondent %)<lb/> Quite a bit troubled<lb/> 16<lb/> 20<lb/> 14<lb/> 15<lb/> 9<lb/> 16<lb/> Extremely troubled<lb/> 14<lb/> 12<lb/> 13<lb/> 14<lb/> 19<lb/> 19<lb/> AR sleep interference (lack of a good night&apos;s sleep) (respondent %)<lb/> Quite a bit troubled<lb/> 15<lb/> 13<lb/> 16<lb/> 18<lb/> 13<lb/> 22<lb/> Extremely troubled<lb/> 14<lb/> 14<lb/> 14<lb/> 15<lb/> 15<lb/> 20<lb/> </table>
<lb/> 
            <note>AR ϭ allergic rhinitis; QOL ϭ quality of life.<lb/> <note>S8<lb/> November-December 2012, Vol. 26, No. 6<lb/> </note>
<lb/> 
            <table>D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>6 </label>
 
            <head>Current status of AR control and treatment in the Middle East<lb/> </head>
<lb/> 
            <table>Parameter<lb/> Middle East<lb/> Egypt<lb/> Iran<lb/> Lebanon<lb/> Saudi Arabia<lb/> United Arab Emirates<lb/> Respondents that have seen a doctor or healthcare provider in the past year (%)<lb/> AR<lb/> 80<lb/> 81<lb/> 98<lb/> 58<lb/> 38<lb/> 61<lb/> No. of visits (mean)<lb/> 5<lb/> 11<lb/> 4<lb/> 6<lb/> 5<lb/> 3<lb/> Frequency of visits to allergist for AR in the past 12 mo (%)<lb/> Monthly or more often<lb/> 22<lb/> 48<lb/> 2<lb/> 4<lb/> 4<lb/> 6<lb/> Several times a year<lb/> 31<lb/> 14<lb/> 58<lb/> 28<lb/> 9<lb/> 14<lb/> Once a year<lb/> 2<lb/> 1<lb/> 2<lb/> 13<lb/> 2<lb/> 4<lb/> Respondents who have been to a pharmacy to get advice about AR (%)<lb/> Past 12 mo<lb/> 22<lb/> 20<lb/> 24<lb/> 26<lb/> 22<lb/> 19<lb/> No. of visits (mean)<lb/> 2<lb/> 2<lb/> 2<lb/> 3<lb/> 3<lb/> 2<lb/> Respondent-perceived AR control in past 4 wk (%)<lb/> Completely or well controlled<lb/> 40<lb/> 24<lb/> 51<lb/> 55<lb/> 48<lb/> 56<lb/> Respondents reporting use of medications for AR within past 4 wk (%)<lb/> No medication<lb/> 14<lb/> 9<lb/> 2<lb/> 25<lb/> 51<lb/> 53<lb/> Any medication<lb/> 86<lb/> 91<lb/> 98<lb/> 75<lb/> 49<lb/> 47<lb/> Any prescription medication<lb/> 83<lb/> 88<lb/> 98<lb/> 75<lb/> 38<lb/> 40<lb/> Other prescription medication<lb/> 46<lb/> 23<lb/> 83<lb/> 61<lb/> 14<lb/> 22<lb/> Steroid spray<lb/> 76<lb/> 80<lb/> 95<lb/> 44<lb/> 30<lb/> 33<lb/> OTC medication<lb/> 20<lb/> 16<lb/> 24<lb/> 9<lb/> 26<lb/> 16<lb/> Respondents reporting use of medications for AR within past 12 mo (%)<lb/> Any medication<lb/> 92<lb/> 93<lb/> 100<lb/> 96<lb/> 69<lb/> 77<lb/> Oral allergy medications<lb/> 53<lb/> 64<lb/> 56<lb/> 49<lb/> 22<lb/> 27<lb/> Desensitization or immunotherapies<lb/> 42<lb/> 51<lb/> 41<lb/> 57<lb/> 19<lb/> 25<lb/> Nasal steroids<lb/> 84<lb/> 83<lb/> 98<lb/> 67<lb/> 59<lb/> 51<lb/> AR ϭ allergic rhinitis; OTC ϭ over the counter.<lb/> American Journal of Rhinology &amp; Allergy<lb/> S9<lb/> D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27<lb/> Copyright (c) Oceanside Publications, Inc. All rights reserved.<lb/> For permission to copy go to https://www.oceansidepubl.com/permission.htm<lb/> </note>
<lb/> 
            <head>Table </head>
 
            <label>7 </label>
 
            <head>AR treatment expectations from Middle East patients<lb/> Parameter<lb/> Middle East Egypt<lb/> Iran<lb/> Lebanon Saudi Arabia United Arab Emirates<lb/> </head>
<lb/> 
            <table>Respondent reported satisfaction with prescription AR medication (%)<lb/> Very satisfied<lb/> 23<lb/> 17<lb/> 23<lb/> 54<lb/> 0<lb/> Somewhat satisfied<lb/> 67<lb/> 74<lb/> 66<lb/> 32<lb/> 100<lb/> Somewhat dissatisfied<lb/> 10<lb/> 4<lb/> 11<lb/> 12<lb/> 0<lb/> Very dissatisfied<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> Respondent perception of relief from other prescription medication taken in past 4 wk (%)<lb/> All symptoms relieved<lb/> 9<lb/> 4<lb/> 8<lb/> 58<lb/> 0<lb/> Most symptoms relieved<lb/> 66<lb/> 61<lb/> 70<lb/> 29<lb/> 0<lb/> Some symptoms relieved<lb/> 25<lb/> 35<lb/> 22<lb/> 14<lb/> 100<lb/> Respondent reported frequency of using nonprescription medications in the last 4 wk for nasal allergies (%)<lb/> Several times a day<lb/> 7<lb/> 0<lb/> 4<lb/> 29<lb/> 11<lb/> Once a day<lb/> 29<lb/> 14<lb/> 21<lb/> 57<lb/> 68<lb/> Several times a week<lb/> 40<lb/> 0<lb/> 63<lb/> 0<lb/> 16<lb/> Once a week<lb/> 7<lb/> 0<lb/> 13<lb/> 0<lb/> 0<lb/> Less than once a week<lb/> 1<lb/> 0<lb/> 0<lb/> 14<lb/> 5<lb/> Respondent reported satisfaction with nonprescription medication taken for nasal allergies (%)<lb/> Very satisfied<lb/> 38<lb/> 29<lb/> 46<lb/> 14<lb/> 26<lb/> Somewhat satisfied<lb/> 54<lb/> 71<lb/> 46<lb/> 71<lb/> 63<lb/> Somewhat dissatisfied<lb/> 5<lb/> 0<lb/> 4<lb/> 0<lb/> 11<lb/> Very dissatisfied<lb/> 0<lb/> 0<lb/> 0<lb/> 14<lb/> 0<lb/> Respondent attitude towards treatment of AR (% somewhat to strongly agreeing)<lb/> There are no truly effective treatments<lb/> 44<lb/> 67<lb/> 10<lb/> 50<lb/> 62<lb/> Frequent symptoms can be prevented in most cases<lb/> 55<lb/> 57<lb/> 46<lb/> 76<lb/> 64<lb/> Nasal steroid sprays are safe<lb/> 60<lb/> 35<lb/> 93<lb/> 56<lb/> 50<lb/> Respondent perception of how quickly nasal steroids are supposed to provide AR symptom relief (%)<lb/> Within 1 hr<lb/> 53<lb/> 63<lb/> 46<lb/> 96<lb/> 40<lb/> 1-3 hr<lb/> 38<lb/> 31<lb/> 47<lb/> 3<lb/> 36<lb/> 4-6 hr<lb/> 5<lb/> 1<lb/> 6<lb/> 0<lb/> 9<lb/> 7-9 hr<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 10-12 hr<lb/> 1<lb/> 1<lb/> 0<lb/> 0<lb/> 2<lb/> 13-24 hr<lb/> 0<lb/> 0<lb/> 0<lb/> 2<lb/> 0<lb/> Ն25 hr<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> Not sure<lb/> 3<lb/> 3<lb/> 1<lb/> 0<lb/> 13<lb/> Respondent perception of how long nasal steroids are supposed to provide AR symptom relief (%)<lb/> Ͻ6 hr<lb/> 62<lb/> 31<lb/> 90<lb/> 20<lb/> 60<lb/> 6-11 hr<lb/> 24<lb/> 56<lb/> 2<lb/> 18<lb/> 11<lb/> 12-17 hr<lb/> 5<lb/> 10<lb/> 0<lb/> 14<lb/> 4<lb/> 18-23 hr<lb/> 1<lb/> 1<lb/> 0<lb/> 8<lb/> 0<lb/> Ն24 hr<lb/> 2<lb/> 0<lb/> 0<lb/> 41<lb/> 7<lb/> Not sure<lb/> 7<lb/> 1<lb/> 7<lb/> 0<lb/> 18<lb/> Respondent perception of most important reason when choosing a nasal steroid (%)<lb/> Fast symptom relief<lb/> 40<lb/> 46<lb/> 36<lb/> 44<lb/> 29<lb/> Long-lasting symptom relief<lb/> 21<lb/> 7<lb/> 31<lb/> 31<lb/> 26<lb/> Complete symptom relief<lb/> 21<lb/> 32<lb/> 12<lb/> 18<lb/> 26<lb/> Few side effects<lb/> 10<lb/> 10<lb/> 11<lb/> 3<lb/> 3<lb/> Easy to take<lb/> 3<lb/> 0<lb/> 5<lb/> 0<lb/> 6<lb/> Low cost<lb/> 2<lb/> 0<lb/> 4<lb/> 2<lb/> 0<lb/> I do not use<lb/> 1<lb/> 2<lb/> 0<lb/> 0<lb/> 0<lb/> Not sure<lb/> 2<lb/> 3<lb/> 1<lb/> 0<lb/> 9<lb/> Respondent perception of length of time (hr) until relief of symptoms from a successful nasal steroid (%)<lb/> Mean<lb/> 2<lb/> 2<lb/> 1<lb/> 2<lb/> 10<lb/> Respondent perception of duration of symptom relief from a successful nasal steroid (%)<lb/> Ͻ4 hr<lb/> 59<lb/> 19<lb/> 94<lb/> 10<lb/> 49<lb/> 4-7 hr<lb/> 14<lb/> 25<lb/> 5<lb/> 7<lb/> 14<lb/> 8-11 hr<lb/> 12<lb/> 27<lb/> 0<lb/> 7<lb/> 14<lb/> 12-15 hr<lb/> 4<lb/> 9<lb/> 0<lb/> 20<lb/> 0<lb/> 16-23 hr<lb/> 6<lb/> 16<lb/> 0<lb/> 3<lb/> 0<lb/> Ն24 hr<lb/> 1<lb/> 0<lb/> 0<lb/> 54<lb/> 3<lb/> Do not use<lb/> 1<lb/> 0<lb/> 0<lb/> 0<lb/> 6<lb/> Not sure<lb/> 3<lb/> 3<lb/> 0<lb/> 0<lb/> 3<lb/> Respondent perception of percent symptom relief expected from a successful nasal steroid (%)<lb/> Mean<lb/> 82<lb/> 90<lb/> 77<lb/> 90<lb/> 71<lb/> AR ϭ allergic rhinitis.<lb/> </table>
<lb/> 
            <note>S10<lb/> November-December 2012, Vol. 26, No. 6<lb/> </note>
<lb/> 
            <table>D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27<lb/> Copyright (c) Oceanside Publications, Inc. All rights reserved.<lb/> For permission to copy go to https://www.oceansidepubl.com/permission.htm<lb/> </note>
<lb/> 
            <head>Table </head>
 
            <label>8 </label>
 
            <head>Nasal steroid spray use and satisfaction in the Middle East<lb/> </head>
<lb/> 
            <table>Parameter<lb/> Middle East<lb/> Egypt<lb/> Iran<lb/> Lebanon<lb/> Saudi Arabia<lb/> United Arab Emirates<lb/> Respondent reported most recent use of nasal steroids for AR symptom relief (%)<lb/> Within past 4 wk<lb/> 76<lb/> 80<lb/> 95<lb/> 44<lb/> 30<lb/> 33<lb/> Within past 6 mo<lb/> 5<lb/> 2<lb/> 3<lb/> 19<lb/> 17<lb/> 12<lb/> Within past year<lb/> 2<lb/> 1<lb/> 0<lb/> 4<lb/> 12<lb/> 6<lb/> 1-2 yr ago<lb/> 2<lb/> 3<lb/> 0<lb/> 7<lb/> 5<lb/> 5<lb/> Ն3 yr<lb/> 1<lb/> 0<lb/> 0<lb/> 5<lb/> 8<lb/> 3<lb/> Never<lb/> 4<lb/> 3<lb/> 1<lb/> 20<lb/> 0<lb/> 39<lb/> Not sure<lb/> 9<lb/> 11<lb/> 1<lb/> 1<lb/> 28<lb/> 3<lb/> Respondent reported mean number of weeks they have taken nasal steroid in the past year (%)<lb/> Weeks of therapy<lb/> 20<lb/> 2<lb/> 32<lb/> 6<lb/> 26<lb/> 8<lb/> Respondent (not used nasal steroid in past year; n ϭ129)-reported reason for not using nasal steroid spray in the past 4 wk (%)<lb/> Symptoms are not bad enough<lb/> 27<lb/> 29<lb/> NA<lb/> 36<lb/> 32<lb/> 18<lb/> Did not like sprays<lb/> 17<lb/> 14<lb/> NA<lb/> 21<lb/> 26<lb/> 0<lb/> Worried about dependence<lb/> 13<lb/> 43<lb/> NA<lb/> 3<lb/> 5<lb/> 0<lb/> Side effects<lb/> 7<lb/> 29<lb/> NA<lb/> 3<lb/> 0<lb/> 0<lb/> No symptoms<lb/> 7<lb/> 0<lb/> NA<lb/> 18<lb/> 0<lb/> 31<lb/> Not effective<lb/> 4<lb/> 14<lb/> NA<lb/> 3<lb/> 0<lb/> 2<lb/> Did not tolerate well<lb/> 0<lb/> 0<lb/> NA<lb/> 3<lb/> 0<lb/> 0<lb/> Hard to use<lb/> 0<lb/> 0<lb/> NA<lb/> 0<lb/> 0<lb/> 0<lb/> Not sure<lb/> 9<lb/> 0<lb/> NA<lb/> 3<lb/> 0<lb/> 29<lb/> Respondent-reported degree AR symptom relief obtained with nasal steroids (%)<lb/> All symptoms<lb/> 22<lb/> 19<lb/> 21<lb/> 51<lb/> 39<lb/> 27<lb/> Most symptoms<lb/> 58<lb/> 66<lb/> 54<lb/> 37<lb/> 22<lb/> 41<lb/> Some symptoms<lb/> 17<lb/> 12<lb/> 20<lb/> 12<lb/> 39<lb/> 27<lb/> No symptoms<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 3<lb/> Respondents reporting nasal steroid has lost efficacy from when it was first taken (%)<lb/> Less effective than when first took it<lb/> 41<lb/> 75<lb/> 8<lb/> 61<lb/> 50<lb/> 53<lb/> Respondent-reported duration of nasal steroid effectiveness (%)<lb/> Ͻ4 hr<lb/> 49<lb/> 56<lb/> 0<lb/> 37<lb/> 44<lb/> 28<lb/> 4-7 hr<lb/> 15<lb/> 14<lb/> 0<lb/> 34<lb/> 33<lb/> 44<lb/> 8-11 hr<lb/> 16<lb/> 19<lb/> 0<lb/> 10<lb/> 0<lb/> 11<lb/> 12-15 hr<lb/> 9<lb/> 8<lb/> 25<lb/> 7<lb/> 0<lb/> 0<lb/> 16-23 hr<lb/> 5<lb/> 2<lb/> 25<lb/> 2<lb/> 22<lb/> 0<lb/> Ն24 hr<lb/> 5<lb/> 0<lb/> 50<lb/> 10<lb/> 0<lb/> 11<lb/> Not sure<lb/> 1<lb/> 2<lb/> 0<lb/> 0<lb/> 0<lb/> 6<lb/> Respondents reporting changing nasal steroid spray (%)<lb/> Several times a year<lb/> 18<lb/> 38<lb/> 0<lb/> 7<lb/> 13<lb/> 9<lb/> Once a year<lb/> 6<lb/> 7<lb/> 1<lb/> 4<lb/> 12<lb/> 14<lb/> Every few years<lb/> 4<lb/> 1<lb/> 9<lb/> 3<lb/> 2<lb/> 3<lb/> Only rarely<lb/> 16<lb/> 8<lb/> 25<lb/> 9<lb/> 19<lb/> 9<lb/> Never<lb/> 48<lb/> 29<lb/> 63<lb/> 77<lb/> 51<lb/> 61<lb/> Respondent-reported reason for switching nasal steroid (%)<lb/> Doctor wanted to try something else<lb/> 47<lb/> 69<lb/> 20<lb/> 17<lb/> 33<lb/> 40<lb/> Patient wanted to try something else<lb/> 29<lb/> 30<lb/> 43<lb/> 13<lb/> 4<lb/> 3<lb/> Did not treat some symptoms<lb/> 27<lb/> 41<lb/> 17<lb/> 26<lb/> 2<lb/> 3<lb/> Not lasting long enough<lb/> 24<lb/> 22<lb/> 37<lb/> 0<lb/> 7<lb/> 3<lb/> Asked doctor to change<lb/> 24<lb/> 21<lb/> 32<lb/> 19<lb/> 12<lb/> 14<lb/> Respondent-reported reason for being dissatisfied with nasal steroid (%)<lb/> Did not find it effective<lb/> 43<lb/> 19<lb/> 56<lb/> 37<lb/> 67<lb/> 71<lb/> Bothersome side effects<lb/> 29<lb/> 43<lb/> 22<lb/> 16<lb/> 17<lb/> 7<lb/> Effectiveness began wearing off<lb/> 26<lb/> 48<lb/> 13<lb/> 21<lb/> 17<lb/> 7<lb/> Did not provide 24-hr relief<lb/> 13<lb/> 24<lb/> 6<lb/> 42<lb/> 0<lb/> 7<lb/> Safety concerns<lb/> 10<lb/> 14<lb/> 9<lb/> 0<lb/> 0<lb/> 0<lb/> Hard to administer<lb/> 3<lb/> 5<lb/> 3<lb/> 0<lb/> 0<lb/> 0<lb/> Not covered by insurance<lb/> 2<lb/> 0<lb/> 3<lb/> 5<lb/> 8<lb/> 0<lb/> Other<lb/> 2<lb/> 5<lb/> 0<lb/> 5<lb/> 0<lb/> 7<lb/> Respondent-reported extremely or moderately bothersomeness of side effects with nasal steroids (%)<lb/> Extremely<lb/> Moderately<lb/> Nosebleeds<lb/> 26<lb/> 47<lb/> Bad taste<lb/> 38<lb/> 37<lb/> Burning<lb/> 20<lb/> 56<lb/> Dripping down throat<lb/> 35<lb/> 40<lb/> Dry feeling<lb/> 39<lb/> 37<lb/> American Journal of Rhinology &amp; Allergy<lb/> S11<lb/> D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>8 </label>
 
            <head>Continued<lb/> </head>
<lb/> 
            <table>Parameter<lb/> Middle East<lb/> Egypt<lb/> Iran<lb/> Lebanon<lb/> Saudi Arabia<lb/> United Arab Emirates<lb/> Headaches<lb/> 43<lb/> 37<lb/> Drowsiness<lb/> 24<lb/> 39<lb/> Spray amount uncomfortable<lb/> 25<lb/> 39<lb/> Crusting<lb/> 23<lb/> 49<lb/> Respondent-reported comparison of side effects from other treatments compared with nasal steroids (%)<lb/> More bothersome<lb/> 36<lb/> 25<lb/> 49<lb/> 31<lb/> 9<lb/> 0<lb/> Same<lb/> 35<lb/> 52<lb/> 23<lb/> 30<lb/> 31<lb/> 28<lb/> Less bothersome<lb/> 18<lb/> 9<lb/> 19<lb/> 33<lb/> 46<lb/> 50<lb/> Respondent-reported side effects occurring with some or all of nasal steroids (%)<lb/> All<lb/> Some<lb/> Nosebleeds<lb/> 0<lb/> 15<lb/> Headaches<lb/> 29<lb/> 31<lb/> Drowsiness<lb/> 17<lb/> 45<lb/> Crusting<lb/> 16<lb/> 54<lb/> Uncomfortable<lb/> 19<lb/> 51<lb/> Burning<lb/> 19<lb/> 58<lb/> Drying feeling<lb/> 36<lb/> 43<lb/> Bad taste<lb/> 39<lb/> 44<lb/> Dripping down throat<lb/> 38<lb/> 52<lb/> Respondent-reported satisfaction with nasal steroid used within the past 4 wk (%)<lb/> Very satisfied<lb/> 39<lb/> 38<lb/> 38<lb/> 54<lb/> 61<lb/> 32<lb/> Somewhat satisfied<lb/> 55<lb/> 61<lb/> 53<lb/> 31<lb/> 22<lb/> 53<lb/> Respondent-reported satisfaction with prescription AR medication (%)<lb/> Very satisfied<lb/> 23<lb/> 17<lb/> 23<lb/> 54<lb/> 0<lb/> 46<lb/> Somewhat satisfied<lb/> 67<lb/> 74<lb/> 66<lb/> 32<lb/> 100<lb/> 23<lb/> Somewhat dissatisfied<lb/> 10<lb/> 4<lb/> 11<lb/> 12<lb/> 0<lb/> 15<lb/> Very dissatisfied<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 0<lb/> 8<lb/> Respondent-reported satisfaction with nonprescription medication taken for AR (%)<lb/> Very satisfied<lb/> 38<lb/> 29<lb/> 46<lb/> 14<lb/> 26<lb/> 32<lb/> Somewhat satisfied<lb/> 54<lb/> 71<lb/> 46<lb/> 71<lb/> 63<lb/> 58<lb/> AR ϭ allergic rhinitis.<lb/> S12<lb/> November-December 2012, Vol. 26, No. 6<lb/> D O<lb/> N O<lb/> T<lb/> C O<lb/> P Y<lb/> </table>
<lb/> 
            <note>Delivered by Ingenta to: UCL LIBRARY IP: 46.243.173.27 On: Mon, 20 Mar 2017 08:24:27</note>
		</figure>



    </text>
</tei>

